Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8052W HIGH $2.95
Volume
740.71 K
Value Traded
1.71 M
Short % Float
9.64%
-4.76%Week
-21.95%1 Month
-22.33%3 Month
+49.53%6 Month
-11.82%5 Year
-82.82%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
235.79 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
143.77 M
Total Shares
147.37 M
Float Shares
125.61 M
Insiders
14.76%
Institutions
58.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IFRX Catalyst Timeline
Dated clinical, regulatory and corporate events for InflaRx N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for InflaRx N.V.
481Total events
16Upcoming
110Tier-1 (high impact)
2017 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Gabriela Alperovich appointed SVP & Global Head of Clinical Development
◆Trial InitiationizicopanTrial
Phase 2 planning for izicopan in AAV continues
ANCA-associated vasculitis (AAV)source ↗
▼CHMP Negative OpinionTavneosEx-US Regulatory
CHMP recommended to revoke marketing authorization for Tavneos in EU
ANCA-associated vasculitissource ↗
▼CHMP Negative OpinionTavneosEx-US Regulatory
EMA CHMP recommended revocation of marketing authorization for Tavneos in EU
ANCA-associated vasculitissource ↗
▼Equity OfferingCorporate
Closed $150 million underwritten offering of 75,000,000 ordinary shares at $2.00 per share
▼Equity OfferingCorporate
Pricing of $150 million underwritten offering of ordinary shares at $2.00 per share
◆FDA Feedback ReceivedizicopanFDA Meeting
Largely concluded interactions with FDA regarding optimized clinical development program for izicopan in HS
hidradenitis suppurativasource ↗
▲Preclinical PoCizicopanPreclinical
Favorable reactive metabolite profile for izicopan in human liver microsomes
▼Equity OfferingCorporate
Underwritten registered direct offering of 75,000,000 ordinary shares at $2.00 per share
▲Preclinical PoCizicopanPreclinical
New pre-clinical data: lower reactive metabolite formation of izicopan vs avacopan
▲Preclinical PoCizicopanPreclinical
Izicopan shows no time-dependent CYP3A4 inhibition in Ki-based TDI study
◆R&D DayizicopanPresentation
Capital Markets Day highlighting izicopan in AAV and renal disorders
ANCA-associated vasculitis, aHUS, IgAN, C3Gsource ↗
▲Preclinical PoCizicopanPreclinical
New in vitro findings: izicopan does not exhibit time-dependent inhibition of CYP3A4
▼Trial Stopped FutilityvilobelimabApprovedTrial
Phase 3 trial of vilobelimab in pyoderma gangrenosum terminated early due to futility by IDMC recommendation
pyoderma gangrenosumsource ↗
▼Primary Endpoint MissedvilobelimabApprovedClinical Data
Primary endpoint of complete target ulcer closure not met: 20.8% vilobelimab vs 16.7% placebo
pyoderma gangrenosumsource ↗
◆FDA Feedback ReceivedizicopanFDA Meeting
Prioritizing FDA discussions on izicopan for hidradenitis suppurativa
hidradenitis suppurativasource ↗
◆Late-BreakervilobelimabApprovedPresentation
Late-breaker oral presentation of Phase 3 results for vilobelimab in pyoderma gangrenosum at AAD 2026
pyoderma gangrenosumsource ↗
◆Oral PresentationvilobelimabApprovedPresentation
Late-breaking oral presentation at AAD 2026
pyoderma gangrenosumsource ↗
◆Oral PresentationvilobelimabApprovedPresentation
Late-breaker oral presentation of Phase 3 vilobelimab data in pyoderma gangrenosum at AAD 2026
pyoderma gangrenosumsource ↗
▼Quarterly UpdateCorporate
Received Nasdaq deficiency notice for minimum bid price non-compliance
◆Oral PresentationPresentation
Fireside chat at Leerink Partners Global Healthcare Conference
◆FDA Feedback ReceivedizicopanFDA Meeting
FDA discussions for Phase 2b trial design in HS
hidradenitis suppurativasource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Virtual Presentation
◆Oral PresentationPresentation
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Fireside Chat
▼Restructuring LayoffsCorporate
Workforce reduction of approximately 30% and substantial spending reductions
▼Program DiscontinuationvilobelimabApprovedCorporate
Significant reductions in Gohibic (vilobelimab) commercial spending and related functions
▼Trial DiscontinuedizicopanTrial
Closed third treatment cohort (anti-IgE refractory) in CSU Phase 2a study
chronic spontaneous urticariasource ↗
◆R&D DayizicopanPresentation
Virtual capital markets day this spring highlighting izicopan clinical utility
◆Topline ReadoutvilobelimabApprovedClinical Data
Primary intent-to-treat analysis and post-hoc analyses disclosed
pyoderma gangrenosumsource ↗
◆Pipeline PrioritizationCorporate
Prioritization of izicopan (INF904) development; vilobelimab PG development deprioritized
◆Trial CompletionINF904Trial
Phase 2a study continues toward completion of 4-week post-treatment observation period
Chronic Spontaneous Urticariasource ↗
◆Oral PresentationPresentation
Fireside chat at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
◆Topline ReadoutINF904Clinical Data
Topline data from Phase 2a trial of INF904 in HS and CSU
hidradenitis suppurativasource ↗
◆Oral PresentationINF904Presentation
Webcast to discuss topline data with KOL insight
hidradenitis suppurativasource ↗
◆Enrollment UpdateINF904Trial
Enrollment ongoing in third CSU dosing cohort (120 mg) in patients refractory to anti-IgE therapy
Chronic Spontaneous Urticariasource ↗
▲Topline ReadoutizicopanClinical Data
Positive topline data from Phase 2a basket study in HS and CSU
chronic spontaneous urticariasource ↗
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference Presentation
◆Topline ReadoutINF904Clinical Data
Topline results from Phase 2a basket study in HS and CSU
chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS)source ↗
Past FDA Catalysts and PDUFA Decisions
How IFRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-01 | izicopan (INF904) | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$8M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 65%
Micro Cap(rank 429 of 660)
Percentile Rank
InflaRx N.V. faces pipeline headwinds (31/100), with $373M risk-adjusted pipeline value, led by IFX-1 in Severe COVID-19 Pneumonia (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IFX-1 Monoclonal antibodyCompletedNCT02866825 | Systemic Inflammatory Response Syndrome | Phase 2 | COMPLETED | 116 | Jan 1, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every IFRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| izicopan | hidradenitis suppurativa, chronic spontaneous urticaria | Phase 2a | 2026-10-02 | ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period; rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels; robust HiSCR responses that continued to deepen four weeks after the treatment period; substantial reductions in patient-reported pain scores; substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients; improved disease control as measured by the Urticaria Control Test (UCT7)Read More | InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IFRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.8 % | 32.48 M | 14.50 M |
IFRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IFRX ranks across every disease it competes in
Competitive Position is a premium feature
See how IFRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIFRX News
IFRXInflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
InflaRx N.V. has been selected to present late-breaking pre-clinical data on izicopan at Kidney Week 2026. The poster will highlight izicopan's potential as a second-generation oral C5a receptor antagonist in kidney disease models. The drug has demonstrated a favorable safety profile and significant therapeutic effects in various clinical studies.
Read more →IFRX▼ -5%on this newsshared move
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
InflaRx N.V. has appointed Dr. Gabriela Alperovich as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich brings over 20 years of experience in the pharmaceutical industry, particularly in immune-inflammatory diseases. Her expertise will be crucial as InflaRx advances its lead program, izicopan, targeting renal and complement-driven diseases.
Read more →IFRXInflaRx to Host Virtual Capital Markets Day
InflaRx N.V. will host a virtual Capital Markets Event on November 3, 2026, featuring discussions on ANCA-associated vasculitis and the company's drug izicopan. Key opinion leaders will provide insights into the treatment landscape and the drug's potential advantages. The event aims to update stakeholders on InflaRx's clinical development strategy.
Read more →IFRXInflaRx Announces Participation in September Investor Conferences
InflaRx N.V. will participate in two investor conferences in September 2026, including the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference. The company will conduct fireside chats and one-on-one investor meetings at both events. InflaRx is known for its innovative anti-inflammatory therapeutics, particularly its lead program, izicopan.
Read more →IFRXInflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
InflaRx N.V. reported its second-quarter results for 2026, highlighting significant progress in the development of izicopan for ANCA-associated vasculitis and renal diseases. The company has a solid financial footing with €158.4 million in cash and plans to initiate a PK bridging study in China. A Capital Markets Day is scheduled for October 8, 2026, to discuss future strategies.
Read more →IFRXInflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx N.V. has announced it will report its second quarter 2026 financial results on August 6, 2026, prior to market opening. The company focuses on developing anti-inflammatory therapeutics, with its lead program izicopan showing promising results in clinical studies. No conference call is scheduled for this announcement.
Read more →IFRXInflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
InflaRx is evaluating a broader strategy for ANCA-associated vasculitis (AAV) in Europe following an EMA recommendation to revoke Tavneos' marketing authorization. The company plans to engage with the EMA regarding its anti-C5a antibody vilobelimab and the oral C5aR inhibitor izicopan. Despite regulatory challenges, Phase 2 planning with izicopan continues as scheduled.
Read more →IFRXInflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has completed an underwritten offering of 75 million ordinary shares at $2.00 each, raising $150 million. The proceeds will be utilized to further develop its pipeline and for general corporate needs. The offering saw participation from various investors, including prominent healthcare funds. Guggenheim Securities led the offering.
Read more →IFRX▲ +26.9%on this newsshared move
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 each, aiming to raise $150 million. The proceeds will be utilized for advancing pipeline activities and general corporate purposes. The offering is set to close on May 7, 2026, pending customary conditions.
Read more →IFRX▲ +26.9%on this newsshared move
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx N.V. is advancing izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other renal diseases. The company plans to conduct Phase 2 studies and aims to establish proof of concept in additional life-threatening kidney disorders. A Capital Markets Day is scheduled for summer 2026 to discuss izicopan's potential. InflaRx has sufficient funding to support its development programs through 2029.
Read more →IFRXInflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx announced favorable pre-clinical data for izicopan, showing low reactive metabolite formation in human liver microsomes. This suggests a lower bioactivation-related safety risk compared to avacopan, a marketed C5aR1 inhibitor. The results support izicopan's potential for improved efficacy and safety in treating inflammatory diseases. The company aims to further validate these findings in clinical studies.
Read more →IFRXInflaRx to Report First Quarter 2026 Results on May 7, 2026
InflaRx N.V. will release its financial results for Q1 2026 on May 7, 2026, prior to market opening. The company is known for its innovative anti-inflammatory therapeutics targeting the complement system, particularly through its lead program izicopan. No conference call is scheduled for this announcement.
Read more →IFRXInflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx N.V. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This compliance is crucial for the company's continued listing on Nasdaq and reflects positively on its market performance.
Read more →IFRXThis is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch
InflaRx N.V. has enacted a deed of amendment to its articles of association, as decided during a general meeting of shareholders in Amsterdam. The amendment involves particular changes to the company's structure and share capital, with a specific focus on adjusting nominal values. The changes are set to take effect upon the issued share capital reaching a stipulated amount. This amendment follows a previous adjustment made in April 2025.
Read more →IFRX▲ +8.4%on this news· ran to +20% by day 3
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx N.V. has reported new in vitro data indicating that izicopan, an oral C5a receptor inhibitor, does not cause time-dependent inhibition of CYP3A4, which is crucial for assessing drug-drug interactions. This finding supports izicopan's potential as a best-in-class treatment for inflammatory diseases. The drug has demonstrated favorable pharmacokinetic and pharmacodynamic profiles in clinical studies.
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2026 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
InflaRx N.V. has issued a convening notice for its 2026 annual general meeting scheduled for April 23, 2026, in Amsterdam. The agenda includes the adoption of the annual accounts for 2025, reappointments of key executives, and auditor nomination. The company has also reiterated its policy of not paying dividends in the foreseeable future, focusing instead on retaining funds for business development. Shareholders must follow specific protocols to attend or vote at the AGM.
Read more →IFRX▲ +7.5%on this newsshared move
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
InflaRx N.V. announced its participation in the Raymond James 2026 Biotech Innovation Symposium, scheduled for April 14, 2026, in New York. The company will engage in one-on-one investor meetings during the event. InflaRx focuses on anti-inflammatory therapeutics, with its lead program izicopan showing promise in clinical studies for inflammatory diseases.
Read more →IFRX▼ -8.8%on this newsshared move
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
InflaRx presented promising Phase 3 data for vilobelimab in treating pyoderma gangrenosum at the 2026 AAD Annual Meeting. The study showed higher rates of complete remission and ulcer closure compared to placebo, alongside a favorable safety profile. However, the trial was halted early due to futility, raising concerns about its efficacy. The company is exploring further development options for vilobelimab.
Read more →IFRXInflaRx Reports Full Year 2025 Results Key Achievements and Expected Milestones
InflaRx N.V. reported strong financial results for 2025 and highlighted key achievements in its therapeutic pipeline, particularly focusing on izicopan for hidradenitis suppurativa and chronic spontaneous urticaria. The CEO emphasized the promising Phase 2a clinical data, which showed rapid and meaningful treatment effects. The company plans to advance izicopan towards Phase 2b trials and is actively engaging with the FDA for further development. Additional focus on other indications and a clear path forward is expected to position InflaRx favorably in the market.
Read more →IFRXInflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
InflaRx N.V. has announced a late-breaking oral presentation for their Phase 3 results of vilobelimab in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting. The presentation, led by Dr. Benjamin Kaffenberger, will take place on March 28, 2026. InflaRx aims to highlight the significance of their findings regarding C5a/C5aR inhibition in the treatment of inflammatory diseases.
Read more →About InflaRx N.V.
BIOPHARMAWATCH ELITE PLUS
Trade the next IFRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime